Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941769 · ClinicalTrials.gov registry record · Phase 1
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03941769: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03941769 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03941769, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I/II trial studies side effects and best dose of recombinant interleukin-7 in promoting immune cell recovery in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, or myeloproliferative disease after a haploidentical or cord blood stem cell transplant. A haploidentical transplant is a transplant that uses stem cells from a donor that is partially (at least 50%) matched to the patient. Umbilical cord blood is a source of blood-forming cells that can be used for transplant, also known as a graft. However, there is a small number of blood-forming cells available in the transplant, which may delay the "take" of the graft in the recipient. Recombinant interleukin-7 may affect the "take" of the graft and the recovery of certain blood cells related to the immune system (called T-cells, natural killer cells, and B cells) in patients who have had a haploidentical or cord blood stem cell transplant.
Interventions
- BIOLOGICAL Recombinant Interleukin-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941769
The ClinicalTrials.gov registry entry for NCT03941769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Interleukin-7 is the first listed.
NCT03941769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03941769 about?
NCT03941769 is a clinical study titled "2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II". This phase I/II trial studies side effects and best dose of recombinant interleukin-7 in promoting immune cell recovery in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, or myeloproliferative disease after a haploidentical or cord blood stem cell transplant...
What is the current status of trial NCT03941769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-09-29. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT03941769?
The interventions under investigation include: Recombinant Interleukin-7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03941769?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.